GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

Food and Healthcare Press Releases Wednesday July 15, 2020 16:28
Bangkok--15 Jul--ABM Connect

GSK and Medicago today announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. Use of an adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

Pre-clinical results with Medicago’s CoVLP vaccine candidate demonstrated a high level of neutralizing antibodies following a single dose when administered with adjuvant.

Phase 1 clinical testing is planned to start in mid-July and will evaluate the safety and immunogenicity of three different dose levels of antigen combined with GSKs pandemic adjuvant and in parallel with an adjuvant from another company, administered on a one- and two-dose vaccination schedule, given 21 days apart.

Subject to successful clinical development and regulatory considerations, the companies aim to complete development and make the vaccine available, in the first half of 2021. Both companies will also evaluate expanding their collaboration to develop a post-pandemic vaccine COVID-19 candidate, should the need arise based on the further development of COVID-19 after the pandemic, and other infectious diseases.

The companies will use Medicago’s plant-based production platform to manufacture the COVID-19 vaccine antigen. This innovative technology uses the leaves of a plant as bioreactors to produce the S-spike protein which self-assemble into VLPs for use in the CoVLP vaccine candidate. It is highly scalable and can support the production of large amounts of vaccine in a significantly shortened timeline. Using this technology combined with GSKs proprietary adjuvant system, the companies expect to be able to manufacture approximately 100m doses by the end of 2021. By the end of 2023, a large-scale facility under construction in Quebec City, Canada, is expected to deliver up to 1 billion doses annually.

Dr Thomas Breuer, Chief Medical Officer, GSK Vaccines, said: “This agreement paves the way for an innovative vaccine option combining a scalable plant-based antigen technology with an adjuvant which has pandemic dose sparing capability. If successful, it will be a meaningful contributor in the fight against COVID-19. We strongly believe that multiple vaccines are needed, including post-pandemic vaccines. This plant-based technology also shows promise beyond COVID-19 and has the potential to help prevent other infectious diseases.”

Dr Bruce Clark, President and CEO of Medicago, said: “We are about to begin clinical trials with our CoVLP vaccine candidate harnessing GSKs pandemic adjuvant technology against the virus that causes COVID-19. This collaboration with GSK gives us access to a proven adjuvant which could enhance the effectiveness of our candidate vaccine, and also to a depth of scientific experience to support our development efforts”


Latest Press Release

How Protein Can Help You Resist Unhealthy Holiday Temptations

By: Susan Bowerman, M.S.,RD,CSSD, CSOWM, FAND – Sr.Director, Worldwide Nutrition Education and Training, Herbalife Nutrition The holidays are a time to be around friends, family,and of course, food. But many of our holiday treats and dishes can...

Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development

Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics, histopathology and genomics services, and Viroclinics-DDL, a provider of preclinical and clinical trial services for vaccine, antiviral, and diagnostic development, are pleased to...

Theptarin Hospital and Chatrium Hotel Riverside Bangkok introduce the 'Sleepless Society Program’ based on the Meditel concept

Meditel is a sensational development in the healthcare field, where people can receive exceptional services without going to hospital, and Chatrium Hotel Riverside Bangkok is in an excellent position to support these healthcare advances. Additionally,...

ผู้นำอุตสาหกรรมระบบแสงสว่างผนึกกำลังนำเสนอแนวปฏิบัติด้านความปลอดภัยของแสงอัลตราไวโอเลต

สมาคม American Lighting Association, National Electrical Manufacturers Association และ UL ได้ออกเอกสารแสดงจุดยืนฉบับใหม่ หวังผลักดันความเสี่ยงในการใช้แสง UVC...

Lighting Industry Leaders Join Forces to Offer Ultraviolet Light Safety Guidance

American Lighting Association, the National Electrical Manufacturers Association and UL bring UVC light application risks to the forefront with new position paper With a shared commitment to the safety and performance of electrical lighting, UL, a...

Related Topics